CA2878928C - Toxicity management for anti-tumor activity of cars - Google Patents
Toxicity management for anti-tumor activity of cars Download PDFInfo
- Publication number
- CA2878928C CA2878928C CA2878928A CA2878928A CA2878928C CA 2878928 C CA2878928 C CA 2878928C CA 2878928 A CA2878928 A CA 2878928A CA 2878928 A CA2878928 A CA 2878928A CA 2878928 C CA2878928 C CA 2878928C
- Authority
- CA
- Canada
- Prior art keywords
- cytokine
- car
- cells
- patient
- leukemia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000001988 toxicity Effects 0.000 title description 15
- 231100000419 toxicity Toxicity 0.000 title description 15
- 230000000259 anti-tumor effect Effects 0.000 title description 14
- 101150102779 Cars1 gene Proteins 0.000 title 1
- 102000004127 Cytokines Human genes 0.000 claims abstract description 210
- 108090000695 Cytokines Proteins 0.000 claims abstract description 210
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 142
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 123
- 239000000427 antigen Substances 0.000 claims abstract description 107
- 108091007433 antigens Proteins 0.000 claims abstract description 103
- 102000036639 antigens Human genes 0.000 claims abstract description 103
- 201000011510 cancer Diseases 0.000 claims abstract description 53
- 230000027455 binding Effects 0.000 claims abstract description 46
- 230000011664 signaling Effects 0.000 claims abstract description 26
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 151
- 206010052015 cytokine release syndrome Diseases 0.000 claims description 74
- 239000003112 inhibitor Substances 0.000 claims description 69
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 50
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 50
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 claims description 49
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 49
- 102000004889 Interleukin-6 Human genes 0.000 claims description 47
- 108090001005 Interleukin-6 Proteins 0.000 claims description 45
- 208000032672 Histiocytosis haematophagic Diseases 0.000 claims description 36
- 239000008194 pharmaceutical composition Substances 0.000 claims description 36
- 201000010099 disease Diseases 0.000 claims description 32
- 230000014509 gene expression Effects 0.000 claims description 32
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 31
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 31
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 31
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims description 28
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 28
- 150000007523 nucleic acids Chemical class 0.000 claims description 24
- 208000004987 Macrophage activation syndrome Diseases 0.000 claims description 22
- 239000003814 drug Substances 0.000 claims description 22
- 102000039446 nucleic acids Human genes 0.000 claims description 22
- 108020004707 nucleic acids Proteins 0.000 claims description 22
- 102000000589 Interleukin-1 Human genes 0.000 claims description 21
- 108010002352 Interleukin-1 Proteins 0.000 claims description 21
- 229940079593 drug Drugs 0.000 claims description 21
- 230000004068 intracellular signaling Effects 0.000 claims description 21
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 21
- 208000032839 leukemia Diseases 0.000 claims description 19
- 229960003989 tocilizumab Drugs 0.000 claims description 19
- 208000035475 disorder Diseases 0.000 claims description 17
- 230000002401 inhibitory effect Effects 0.000 claims description 17
- HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical group N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 claims description 16
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 claims description 16
- 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 claims description 16
- 108010002350 Interleukin-2 Proteins 0.000 claims description 16
- 102000000588 Interleukin-2 Human genes 0.000 claims description 16
- 229960004238 anakinra Drugs 0.000 claims description 16
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 16
- 239000003085 diluting agent Substances 0.000 claims description 15
- 208000036066 Hemophagocytic Lymphohistiocytosis Diseases 0.000 claims description 14
- 208000014752 hemophagocytic syndrome Diseases 0.000 claims description 14
- 230000003834 intracellular effect Effects 0.000 claims description 14
- 108020004459 Small interfering RNA Proteins 0.000 claims description 13
- 108700012920 TNF Proteins 0.000 claims description 13
- 238000000338 in vitro Methods 0.000 claims description 13
- 239000004055 small Interfering RNA Substances 0.000 claims description 13
- 208000008691 Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 12
- 239000013598 vector Substances 0.000 claims description 12
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 11
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 11
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 11
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 11
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 10
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 10
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims description 10
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 10
- 208000014619 adult acute lymphoblastic leukemia Diseases 0.000 claims description 10
- 201000011184 adult acute lymphocytic leukemia Diseases 0.000 claims description 10
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 9
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 9
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 9
- 239000003246 corticosteroid Substances 0.000 claims description 9
- 239000013604 expression vector Substances 0.000 claims description 9
- 206010000830 Acute leukaemia Diseases 0.000 claims description 8
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 8
- 206010025323 Lymphomas Diseases 0.000 claims description 8
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 8
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 7
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims description 6
- 108090000994 Catalytic RNA Proteins 0.000 claims description 6
- 102000053642 Catalytic RNA Human genes 0.000 claims description 6
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims description 6
- 108700011259 MicroRNAs Proteins 0.000 claims description 6
- 230000000692 anti-sense effect Effects 0.000 claims description 6
- 239000002679 microRNA Substances 0.000 claims description 6
- 108091092562 ribozyme Proteins 0.000 claims description 6
- 150000003384 small molecules Chemical class 0.000 claims description 6
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 5
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 claims description 5
- 208000036566 Erythroleukaemia Diseases 0.000 claims description 5
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 5
- 208000017604 Hodgkin disease Diseases 0.000 claims description 5
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 5
- 206010024305 Leukaemia monocytic Diseases 0.000 claims description 5
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 5
- 208000034578 Multiple myelomas Diseases 0.000 claims description 5
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 5
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims description 5
- 208000021841 acute erythroid leukemia Diseases 0.000 claims description 5
- 238000011254 conventional chemotherapy Methods 0.000 claims description 5
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 claims description 5
- 201000009277 hairy cell leukemia Diseases 0.000 claims description 5
- 208000025750 heavy chain disease Diseases 0.000 claims description 5
- 208000037819 metastatic cancer Diseases 0.000 claims description 5
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims description 5
- 229960004584 methylprednisolone Drugs 0.000 claims description 5
- 201000006894 monocytic leukemia Diseases 0.000 claims description 5
- 229940124790 IL-6 inhibitor Drugs 0.000 claims description 3
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 claims 4
- 206010066476 Haematological malignancy Diseases 0.000 claims 4
- 208000017733 acquired polycythemia vera Diseases 0.000 claims 4
- 208000025113 myeloid leukemia Diseases 0.000 claims 4
- 208000037244 polycythemia vera Diseases 0.000 claims 4
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 claims 1
- 238000001802 infusion Methods 0.000 abstract description 71
- 238000002560 therapeutic procedure Methods 0.000 abstract description 61
- 238000000034 method Methods 0.000 abstract description 57
- 239000000203 mixture Substances 0.000 abstract description 33
- 238000009093 first-line therapy Methods 0.000 abstract description 9
- 230000000139 costimulatory effect Effects 0.000 abstract description 5
- 238000012544 monitoring process Methods 0.000 abstract description 5
- 210000004027 cell Anatomy 0.000 description 179
- 108010078373 tisagenlecleucel Proteins 0.000 description 64
- 238000011282 treatment Methods 0.000 description 48
- 239000008280 blood Substances 0.000 description 35
- 210000004369 blood Anatomy 0.000 description 33
- 238000001727 in vivo Methods 0.000 description 25
- 210000003719 b-lymphocyte Anatomy 0.000 description 24
- 239000012472 biological sample Substances 0.000 description 24
- 230000000694 effects Effects 0.000 description 22
- 108090000623 proteins and genes Proteins 0.000 description 22
- 108020004414 DNA Proteins 0.000 description 21
- 230000004044 response Effects 0.000 description 21
- 210000001185 bone marrow Anatomy 0.000 description 20
- 239000000523 sample Substances 0.000 description 19
- 238000003556 assay Methods 0.000 description 18
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 18
- 230000028993 immune response Effects 0.000 description 17
- 210000005259 peripheral blood Anatomy 0.000 description 17
- 239000011886 peripheral blood Substances 0.000 description 17
- -1 1L-4 Proteins 0.000 description 16
- 150000001875 compounds Chemical class 0.000 description 16
- 102000004169 proteins and genes Human genes 0.000 description 15
- 239000003446 ligand Substances 0.000 description 14
- 239000000463 material Substances 0.000 description 14
- 210000003169 central nervous system Anatomy 0.000 description 13
- 102000008857 Ferritin Human genes 0.000 description 12
- 108050000784 Ferritin Proteins 0.000 description 12
- 238000008416 Ferritin Methods 0.000 description 12
- 108060003951 Immunoglobulin Proteins 0.000 description 12
- 239000005557 antagonist Substances 0.000 description 12
- 102000018358 immunoglobulin Human genes 0.000 description 12
- 210000004698 lymphocyte Anatomy 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- 206010037660 Pyrexia Diseases 0.000 description 11
- 230000006698 induction Effects 0.000 description 11
- 238000009094 second-line therapy Methods 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 10
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 10
- 238000002512 chemotherapy Methods 0.000 description 10
- 238000001514 detection method Methods 0.000 description 10
- 238000000684 flow cytometry Methods 0.000 description 10
- 230000035755 proliferation Effects 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- 241000124008 Mammalia Species 0.000 description 9
- 208000007660 Residual Neoplasm Diseases 0.000 description 9
- 230000004913 activation Effects 0.000 description 9
- 239000012190 activator Substances 0.000 description 9
- 230000003321 amplification Effects 0.000 description 9
- 238000003199 nucleic acid amplification method Methods 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 210000000265 leukocyte Anatomy 0.000 description 8
- 230000004936 stimulating effect Effects 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 230000009258 tissue cross reactivity Effects 0.000 description 8
- 206010002961 Aplasia Diseases 0.000 description 7
- 101150013553 CD40 gene Proteins 0.000 description 7
- 208000001953 Hypotension Diseases 0.000 description 7
- 108090000174 Interleukin-10 Proteins 0.000 description 7
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 7
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 7
- 241000713666 Lentivirus Species 0.000 description 7
- 206010039491 Sarcoma Diseases 0.000 description 7
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 7
- 206010045170 Tumour lysis syndrome Diseases 0.000 description 7
- 210000003969 blast cell Anatomy 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 230000036543 hypotension Effects 0.000 description 7
- 108040006849 interleukin-2 receptor activity proteins Proteins 0.000 description 7
- 230000001404 mediated effect Effects 0.000 description 7
- 230000003389 potentiating effect Effects 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 230000032258 transport Effects 0.000 description 7
- 208000010380 tumor lysis syndrome Diseases 0.000 description 7
- 108010008165 Etanercept Proteins 0.000 description 6
- 101000599048 Homo sapiens Interleukin-6 receptor subunit alpha Proteins 0.000 description 6
- 108010038501 Interleukin-6 Receptors Proteins 0.000 description 6
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 description 6
- 230000002411 adverse Effects 0.000 description 6
- 230000000719 anti-leukaemic effect Effects 0.000 description 6
- 210000000612 antigen-presenting cell Anatomy 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 229960000403 etanercept Drugs 0.000 description 6
- 230000036210 malignancy Effects 0.000 description 6
- 238000007726 management method Methods 0.000 description 6
- 230000036961 partial effect Effects 0.000 description 6
- 102000040430 polynucleotide Human genes 0.000 description 6
- 108091033319 polynucleotide Proteins 0.000 description 6
- 239000002157 polynucleotide Substances 0.000 description 6
- 229920001184 polypeptide Polymers 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 238000011269 treatment regimen Methods 0.000 description 6
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 5
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 5
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 5
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 description 5
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 description 5
- 108010055166 Chemokine CCL5 Proteins 0.000 description 5
- 102100023688 Eotaxin Human genes 0.000 description 5
- 101710139422 Eotaxin Proteins 0.000 description 5
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 5
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 5
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 5
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 5
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 5
- 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 description 5
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 description 5
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 5
- 101000868152 Homo sapiens Son of sevenless homolog 1 Proteins 0.000 description 5
- 108010065805 Interleukin-12 Proteins 0.000 description 5
- 108090000176 Interleukin-13 Proteins 0.000 description 5
- 108050003558 Interleukin-17 Proteins 0.000 description 5
- 102000013691 Interleukin-17 Human genes 0.000 description 5
- 102100026019 Interleukin-6 Human genes 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 101710098940 Pro-epidermal growth factor Proteins 0.000 description 5
- 230000005867 T cell response Effects 0.000 description 5
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 5
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 5
- 230000000735 allogeneic effect Effects 0.000 description 5
- 230000010261 cell growth Effects 0.000 description 5
- 239000013068 control sample Substances 0.000 description 5
- 230000008030 elimination Effects 0.000 description 5
- 238000003379 elimination reaction Methods 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 239000003862 glucocorticoid Substances 0.000 description 5
- 208000024908 graft versus host disease Diseases 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 208000021760 high fever Diseases 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 238000003018 immunoassay Methods 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 230000003211 malignant effect Effects 0.000 description 5
- 201000001441 melanoma Diseases 0.000 description 5
- 230000002688 persistence Effects 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 230000002459 sustained effect Effects 0.000 description 5
- 238000011277 treatment modality Methods 0.000 description 5
- 201000009030 Carcinoma Diseases 0.000 description 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 4
- 108090000172 Interleukin-15 Proteins 0.000 description 4
- 108090000978 Interleukin-4 Proteins 0.000 description 4
- 108010002616 Interleukin-5 Proteins 0.000 description 4
- 102000010781 Interleukin-6 Receptors Human genes 0.000 description 4
- 108090001007 Interleukin-8 Proteins 0.000 description 4
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 4
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 4
- 206010060862 Prostate cancer Diseases 0.000 description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 4
- 238000001190 Q-PCR Methods 0.000 description 4
- 102000003929 Transaminases Human genes 0.000 description 4
- 108090000340 Transaminases Proteins 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000002648 combination therapy Methods 0.000 description 4
- 102000003675 cytokine receptors Human genes 0.000 description 4
- 108010057085 cytokine receptors Proteins 0.000 description 4
- 239000012636 effector Substances 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 238000009169 immunotherapy Methods 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 150000003431 steroids Chemical class 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 108091008875 B cell receptors Proteins 0.000 description 3
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 3
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 3
- 108010036949 Cyclosporine Proteins 0.000 description 3
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 description 3
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 3
- 206010021143 Hypoxia Diseases 0.000 description 3
- 244000178870 Lavandula angustifolia Species 0.000 description 3
- 235000010663 Lavandula angustifolia Nutrition 0.000 description 3
- 206010033128 Ovarian cancer Diseases 0.000 description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 3
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 3
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 229960003008 blinatumomab Drugs 0.000 description 3
- 238000010322 bone marrow transplantation Methods 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 229960001265 ciclosporin Drugs 0.000 description 3
- 229960004397 cyclophosphamide Drugs 0.000 description 3
- 229930182912 cyclosporin Natural products 0.000 description 3
- 210000004443 dendritic cell Anatomy 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 206010019847 hepatosplenomegaly Diseases 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 230000007954 hypoxia Effects 0.000 description 3
- 238000013394 immunophenotyping Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000001102 lavandula vera Substances 0.000 description 3
- 235000018219 lavender Nutrition 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000003472 neutralizing effect Effects 0.000 description 3
- 201000002528 pancreatic cancer Diseases 0.000 description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 description 3
- 230000002085 persistent effect Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 208000016800 primary central nervous system lymphoma Diseases 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 229940037128 systemic glucocorticoids Drugs 0.000 description 3
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 240000007241 Agrostis stolonifera Species 0.000 description 2
- 108010083359 Antigen Receptors Proteins 0.000 description 2
- 102000006306 Antigen Receptors Human genes 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 102100035793 CD83 antigen Human genes 0.000 description 2
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 2
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 229930105110 Cyclosporin A Natural products 0.000 description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 description 2
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 2
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 2
- 102000003777 Interleukin-1 beta Human genes 0.000 description 2
- 108090000193 Interleukin-1 beta Proteins 0.000 description 2
- 102000004125 Interleukin-1alpha Human genes 0.000 description 2
- 108010082786 Interleukin-1alpha Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 2
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 description 2
- 206010027406 Mesothelioma Diseases 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 108010062374 Myoglobin Proteins 0.000 description 2
- 102100030856 Myoglobin Human genes 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 101100117488 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) mip-1 gene Proteins 0.000 description 2
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- 230000006052 T cell proliferation Effects 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 108700019146 Transgenes Proteins 0.000 description 2
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 description 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 2
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000010317 ablation therapy Methods 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 2
- 229960003459 allopurinol Drugs 0.000 description 2
- 230000003092 anti-cytokine Effects 0.000 description 2
- 238000009175 antibody therapy Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000003651 basophil Anatomy 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 238000001815 biotherapy Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000007975 buffered saline Substances 0.000 description 2
- 229940112129 campath Drugs 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 239000013626 chemical specie Substances 0.000 description 2
- 208000018805 childhood acute lymphoblastic leukemia Diseases 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 238000012350 deep sequencing Methods 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
- 229960005420 etoposide Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 210000004700 fetal blood Anatomy 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 201000005787 hematologic cancer Diseases 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 210000003630 histaminocyte Anatomy 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000021633 leukocyte mediated immunity Effects 0.000 description 2
- 238000007477 logistic regression Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 2
- 210000003071 memory t lymphocyte Anatomy 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229930192851 perforin Natural products 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000001603 reducing effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 229960002930 sirolimus Drugs 0.000 description 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000002483 superagonistic effect Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 229940116269 uric acid Drugs 0.000 description 2
- BSDCIRGNJKZPFV-GWOFURMSSA-N (2r,3s,4r,5r)-2-(hydroxymethyl)-5-(2,5,6-trichlorobenzimidazol-1-yl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=CC(Cl)=C(Cl)C=C2N=C1Cl BSDCIRGNJKZPFV-GWOFURMSSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- 108010082808 4-1BB Ligand Proteins 0.000 description 1
- 102100023990 60S ribosomal protein L17 Human genes 0.000 description 1
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 240000005611 Agrostis gigantea Species 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 108010074708 B7-H1 Antigen Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010006143 Brain stem glioma Diseases 0.000 description 1
- 102100027207 CD27 antigen Human genes 0.000 description 1
- 102100025221 CD70 antigen Human genes 0.000 description 1
- 101150113634 CDKN1A gene Proteins 0.000 description 1
- 102000004631 Calcineurin Human genes 0.000 description 1
- 108010042955 Calcineurin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- VWFCHDSQECPREK-LURJTMIESA-N Cidofovir Chemical compound NC=1C=CN(C[C@@H](CO)OCP(O)(O)=O)C(=O)N=1 VWFCHDSQECPREK-LURJTMIESA-N 0.000 description 1
- 108091062157 Cis-regulatory element Proteins 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 206010050685 Cytokine storm Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 208000010975 Dystrophic epidermolysis bullosa Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 206010014486 Elevated triglycerides Diseases 0.000 description 1
- 238000011510 Elispot assay Methods 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 206010051841 Exposure to allergen Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000037194 Fever of Unknown Origin Diseases 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 208000000527 Germinoma Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 102100028967 HLA class I histocompatibility antigen, alpha chain G Human genes 0.000 description 1
- 108010024164 HLA-G Antigens Proteins 0.000 description 1
- 208000001204 Hashimoto Disease Diseases 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 1
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 description 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 1
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 description 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 1
- 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 description 1
- 101000984189 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 2 Proteins 0.000 description 1
- 101000984186 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 4 Proteins 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 101001063392 Homo sapiens Lymphocyte function-associated antigen 3 Proteins 0.000 description 1
- 101000763322 Homo sapiens M1-specific T cell receptor beta chain Proteins 0.000 description 1
- 101000991061 Homo sapiens MHC class I polypeptide-related sequence B Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 description 1
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 description 1
- 101000763321 Homo sapiens T cell receptor beta chain MC.7.G5 Proteins 0.000 description 1
- 101000597785 Homo sapiens Tumor necrosis factor receptor superfamily member 6B Proteins 0.000 description 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
- 206010051125 Hypofibrinogenaemia Diseases 0.000 description 1
- 208000001718 Immediate Hypersensitivity Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 102000012745 Immunoglobulin Subunits Human genes 0.000 description 1
- 108010079585 Immunoglobulin Subunits Proteins 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 102000000646 Interleukin-3 Human genes 0.000 description 1
- 229940127448 Interleukin-6 Antagonists Drugs 0.000 description 1
- 108020003285 Isocitrate lyase Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 102100020880 Kit ligand Human genes 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 102100025583 Leukocyte immunoglobulin-like receptor subfamily B member 2 Human genes 0.000 description 1
- 102100025578 Leukocyte immunoglobulin-like receptor subfamily B member 4 Human genes 0.000 description 1
- 208000035967 Long Term Adverse Effects Diseases 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 102100030984 Lymphocyte function-associated antigen 3 Human genes 0.000 description 1
- 108010091221 Lymphotoxin beta Receptor Proteins 0.000 description 1
- 102000018170 Lymphotoxin beta Receptor Human genes 0.000 description 1
- 102100026964 M1-specific T cell receptor beta chain Human genes 0.000 description 1
- 102100030301 MHC class I polypeptide-related sequence A Human genes 0.000 description 1
- 102100030300 MHC class I polypeptide-related sequence B Human genes 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000007054 Medullary Carcinoma Diseases 0.000 description 1
- 208000037196 Medullary thyroid carcinoma Diseases 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000003735 Mesothelin Human genes 0.000 description 1
- 108090000015 Mesothelin Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010059282 Metastases to central nervous system Diseases 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- 101710151805 Mitochondrial intermediate peptidase 1 Proteins 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- 206010028665 Myxoedema Diseases 0.000 description 1
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 102000003729 Neprilysin Human genes 0.000 description 1
- 108090000028 Neprilysin Proteins 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 201000010133 Oligodendroglioma Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010033661 Pancytopenia Diseases 0.000 description 1
- 206010033701 Papillary thyroid cancer Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 206010034038 Parotitis Diseases 0.000 description 1
- 201000011152 Pemphigus Diseases 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- 108010089430 Phosphoproteins Proteins 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 208000007641 Pinealoma Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 1
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 241000712907 Retroviridae Species 0.000 description 1
- 235000014328 Schoenoplectus acutus var occidentalis Nutrition 0.000 description 1
- 244000136421 Scirpus acutus Species 0.000 description 1
- 235000014326 Scirpus californicus Nutrition 0.000 description 1
- 235000017913 Scirpus lacustris Nutrition 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 208000006045 Spondylarthropathies Diseases 0.000 description 1
- 108010039445 Stem Cell Factor Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 108010092262 T-Cell Antigen Receptors Proteins 0.000 description 1
- 101000588258 Taenia solium Paramyosin Proteins 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 210000004241 Th2 cell Anatomy 0.000 description 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 description 1
- 102100035284 Tumor necrosis factor receptor superfamily member 6B Human genes 0.000 description 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 206010045240 Type I hypersensitivity Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 208000014070 Vestibular schwannoma Diseases 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 208000004064 acoustic neuroma Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 238000011366 aggressive therapy Methods 0.000 description 1
- 238000011256 aggressive treatment Methods 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000003302 anti-idiotype Effects 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 238000002617 apheresis Methods 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 208000010216 atopic IgE responsiveness Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 201000007180 bile duct carcinoma Diseases 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 201000001531 bladder carcinoma Diseases 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 208000015294 blood coagulation disease Diseases 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 229940030156 cell vaccine Drugs 0.000 description 1
- 230000005889 cellular cytotoxicity Effects 0.000 description 1
- 201000010039 central nervous system leukemia Diseases 0.000 description 1
- 208000025997 central nervous system neoplasm Diseases 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000012829 chemotherapy agent Substances 0.000 description 1
- 208000011654 childhood malignant neoplasm Diseases 0.000 description 1
- 208000012191 childhood neoplasm Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000024207 chronic leukemia Diseases 0.000 description 1
- 229960000724 cidofovir Drugs 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 230000002153 concerted effect Effects 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 230000036757 core body temperature Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 208000024389 cytopenia Diseases 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000011393 cytotoxic chemotherapy Methods 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960000284 efalizumab Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 208000004298 epidermolysis bullosa dystrophica Diseases 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000011124 ex vivo culture Methods 0.000 description 1
- 238000002710 external beam radiation therapy Methods 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N ferric oxide Chemical compound O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 230000027950 fever generation Effects 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 108090000047 fibroblast growth factor 13 Proteins 0.000 description 1
- 102000003684 fibroblast growth factor 13 Human genes 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 238000002509 fluorescent in situ hybridization Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 201000003115 germ cell cancer Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 201000002222 hemangioblastoma Diseases 0.000 description 1
- 208000013210 hematogenous Diseases 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000011368 intensive chemotherapy Methods 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 208000030208 low-grade fever Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 238000011469 lymphodepleting chemotherapy Methods 0.000 description 1
- 238000007403 mPCR Methods 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005399 mechanical ventilation Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 238000012737 microarray-based gene expression Methods 0.000 description 1
- 201000004058 mixed glioma Diseases 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 238000002887 multiple sequence alignment Methods 0.000 description 1
- 238000012243 multiplex automated genomic engineering Methods 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 229940014456 mycophenolate Drugs 0.000 description 1
- 229960000951 mycophenolic acid Drugs 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 208000003786 myxedema Diseases 0.000 description 1
- 208000001611 myxosarcoma Diseases 0.000 description 1
- 229960005027 natalizumab Drugs 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 208000025189 neoplasm of testis Diseases 0.000 description 1
- 208000007538 neurilemmoma Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000007481 next generation sequencing Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 208000004019 papillary adenocarcinoma Diseases 0.000 description 1
- 201000010198 papillary carcinoma Diseases 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 201000001976 pemphigus vulgaris Diseases 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 230000003094 perturbing effect Effects 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 208000024724 pineal body neoplasm Diseases 0.000 description 1
- 201000004123 pineal gland cancer Diseases 0.000 description 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 210000004986 primary T-cell Anatomy 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 208000030279 prolonged fever Diseases 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 208000037922 refractory disease Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 206010039667 schwannoma Diseases 0.000 description 1
- 201000008407 sebaceous adenocarcinoma Diseases 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 201000005671 spondyloarthropathy Diseases 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 201000010965 sweat gland carcinoma Diseases 0.000 description 1
- 206010042863 synovial sarcoma Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 208000013818 thyroid gland medullary carcinoma Diseases 0.000 description 1
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 description 1
- 206010043778 thyroiditis Diseases 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 230000004222 uncontrolled growth Effects 0.000 description 1
- 230000009452 underexpressoin Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 230000003519 ventilatory effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 238000012447 xenograft mouse model Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/421—Immunoglobulin superfamily
- A61K40/4211—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Bioinformatics & Computational Biology (AREA)
- General Engineering & Computer Science (AREA)
- Endocrinology (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261671482P | 2012-07-13 | 2012-07-13 | |
| US61/671,482 | 2012-07-13 | ||
| US201361782982P | 2013-03-14 | 2013-03-14 | |
| US61/782,982 | 2013-03-14 | ||
| PCT/US2013/050267 WO2014011984A1 (en) | 2012-07-13 | 2013-07-12 | Toxicity management for anti-tumor activity of cars |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2878928A1 CA2878928A1 (en) | 2014-01-16 |
| CA2878928C true CA2878928C (en) | 2023-03-14 |
Family
ID=49916566
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2878928A Active CA2878928C (en) | 2012-07-13 | 2013-07-12 | Toxicity management for anti-tumor activity of cars |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US20150202286A1 (enExample) |
| EP (5) | EP4461308B1 (enExample) |
| JP (6) | JP6382191B2 (enExample) |
| KR (1) | KR102204029B1 (enExample) |
| CN (4) | CN111467494B (enExample) |
| AU (2) | AU2013289967B2 (enExample) |
| BR (1) | BR112015000660A8 (enExample) |
| CA (1) | CA2878928C (enExample) |
| DK (4) | DK3338794T3 (enExample) |
| EA (1) | EA201590210A1 (enExample) |
| ES (4) | ES2941370T3 (enExample) |
| FI (2) | FI4461308T3 (enExample) |
| HR (2) | HRP20250822T1 (enExample) |
| HU (4) | HUE072215T2 (enExample) |
| IN (1) | IN2014DN11155A (enExample) |
| LT (4) | LT4461308T (enExample) |
| MX (2) | MX2015000438A (enExample) |
| PL (3) | PL4461308T3 (enExample) |
| PT (4) | PT4019041T (enExample) |
| SI (2) | SI4019041T1 (enExample) |
| WO (1) | WO2014011984A1 (enExample) |
Families Citing this family (117)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2941370T3 (es) | 2012-07-13 | 2023-05-22 | Univ Pennsylvania | Control de la toxicidad para la actividad antitumoral de los CAR |
| US20150320799A1 (en) | 2012-12-20 | 2015-11-12 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| EP2958943B1 (en) | 2013-02-20 | 2019-09-11 | The Trustees Of The University Of Pennsylvania | Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor |
| WO2014130635A1 (en) | 2013-02-20 | 2014-08-28 | Novartis Ag | Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells |
| US9745368B2 (en) | 2013-03-15 | 2017-08-29 | The Trustees Of The University Of Pennsylvania | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| TWI654206B (zh) | 2013-03-16 | 2019-03-21 | 諾華公司 | 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症 |
| SG11201604815RA (en) | 2013-12-19 | 2016-07-28 | Novartis Ag | Human mesothelin chimeric antigen receptors and uses thereof |
| US10287354B2 (en) | 2013-12-20 | 2019-05-14 | Novartis Ag | Regulatable chimeric antigen receptor |
| US11028143B2 (en) | 2014-01-21 | 2021-06-08 | Novartis Ag | Enhanced antigen presenting ability of RNA CAR T cells by co-introduction of costimulatory molecules |
| LT3129470T (lt) * | 2014-04-07 | 2021-07-12 | Novartis Ag | Vėžio gydymas naudojant anti-cd19 chimerinį antigeno receptorių |
| CA2946511C (en) | 2014-04-21 | 2023-08-22 | The Childen's Hospital Of Philadelphia | Compositions and methods for treating cytokine-related disorders |
| BR112017001183A2 (pt) | 2014-07-21 | 2017-11-28 | Novartis Ag | tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado |
| WO2016014553A1 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
| CN107109419B (zh) | 2014-07-21 | 2020-12-22 | 诺华股份有限公司 | 使用cd33嵌合抗原受体治疗癌症 |
| SG11201700418VA (en) | 2014-07-21 | 2017-02-27 | Novartis Ag | Treatment of cancer using a cll-1 chimeric antigen receptor |
| ES2791248T3 (es) | 2014-08-19 | 2020-11-03 | Novartis Ag | Receptor antigénico quimérico (CAR) anti-CD123 para su uso en el tratamiento del cáncer |
| EA201790624A1 (ru) | 2014-09-17 | 2017-08-31 | Новартис Аг | Нацеливание цитотоксических клеток с химерными рецепторами для адоптивной иммунотерапии |
| AU2015330898B2 (en) | 2014-10-08 | 2022-03-10 | Novartis Ag | Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof |
| AU2015374296B2 (en) | 2014-12-29 | 2021-09-02 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| US11459390B2 (en) | 2015-01-16 | 2022-10-04 | Novartis Ag | Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor |
| US11161907B2 (en) | 2015-02-02 | 2021-11-02 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| SG11201706236SA (en) * | 2015-02-06 | 2017-08-30 | Nat Univ Singapore | Methods for enhancing efficacy of therapeutic immune cells |
| US11497767B2 (en) | 2015-02-18 | 2022-11-15 | Enlivex Therapeutics R&D Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| KR20170117450A (ko) * | 2015-02-18 | 2017-10-23 | 엔리벡스 테라퓨틱스 리미티드 | 암 치료를 위한 면역 요법 및 사이토카인 조절 요법의 조합 |
| US11304976B2 (en) | 2015-02-18 | 2022-04-19 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11000548B2 (en) | 2015-02-18 | 2021-05-11 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11318163B2 (en) | 2015-02-18 | 2022-05-03 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11596652B2 (en) | 2015-02-18 | 2023-03-07 | Enlivex Therapeutics R&D Ltd | Early apoptotic cells for use in treating sepsis |
| WO2017141243A1 (en) * | 2016-02-18 | 2017-08-24 | Enlivex Therapeutics Ltd. | Combination immune therapy and cytokine control therapy for cancer treatment |
| WO2016170541A1 (en) | 2015-04-21 | 2016-10-27 | Enlivex Therapeutics Ltd. | Therapeutic pooled blood apoptotic cell preparations and uses thereof |
| SG11201708191XA (en) | 2015-04-08 | 2017-11-29 | Novartis Ag | Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell |
| EP4234685A3 (en) | 2015-04-17 | 2023-09-06 | Novartis AG | Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells |
| US12128069B2 (en) | 2015-04-23 | 2024-10-29 | The Trustees Of The University Of Pennsylvania | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
| CN109476722A (zh) | 2015-07-21 | 2019-03-15 | 诺华股份有限公司 | 用于改善免疫细胞的功效和扩张的方法 |
| WO2017027392A1 (en) | 2015-08-07 | 2017-02-16 | Novartis Ag | Treatment of cancer using chimeric cd3 receptor proteins |
| CN108780084B (zh) * | 2015-09-03 | 2022-07-22 | 诺华股份有限公司 | 预测细胞因子释放综合征的生物标志物 |
| MA44909A (fr) | 2015-09-15 | 2018-07-25 | Acerta Pharma Bv | Association thérapeutique d'un inhibiteur du cd19 et d'un inhibiteur de la btk |
| ES2988976T3 (es) | 2015-11-27 | 2024-11-22 | Cartherics Pty Ltd | Células modificadas genéticamente y usos de estas |
| MA43377A (fr) | 2015-12-04 | 2021-05-19 | Hutchinson Fred Cancer Res | Méthodes et compositions liées à la toxicité associée à la thérapie cellulaire |
| CN121294437A (zh) | 2015-12-04 | 2026-01-09 | 诺华股份有限公司 | 用于免疫肿瘤学的组合物和方法 |
| MA44140A (fr) | 2015-12-22 | 2021-05-19 | Dana Farber Cancer Inst Inc | Récepteur d'antigène chimérique (car) contre la mésothéline et anticorps contre l'inhibiteur de pd-l1 pour une utilisation combinée dans une thérapie anticancéreuse |
| JP6853514B2 (ja) * | 2015-12-27 | 2021-03-31 | 国立大学法人東海国立大学機構 | 炎症性サイトカインの産生が抑制されるキメラ抗原受容体遺伝子改変リンパ球 |
| US11325948B2 (en) | 2016-03-19 | 2022-05-10 | Exuma Biotech Corp. | Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL |
| US11111505B2 (en) | 2016-03-19 | 2021-09-07 | Exuma Biotech, Corp. | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
| MA71266A (fr) * | 2016-03-22 | 2025-04-30 | Seattle Children's Hospital(DBA Seattle Children's Research Institute) | Procédés d'intervention précoce pour prévenir ou améliorer la toxicité |
| EP3432924A1 (en) | 2016-03-23 | 2019-01-30 | Novartis AG | Cell secreted minibodies and uses thereof |
| CA3019835A1 (en) | 2016-04-08 | 2017-10-12 | Purdue Research Foundation | Methods and compositions for car t cell therapy |
| EP3445407B1 (en) | 2016-04-22 | 2022-12-14 | CRAGE medical Co., Limited | Compositions and methods of cellular immunotherapy |
| WO2017189959A1 (en) | 2016-04-29 | 2017-11-02 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| WO2017189964A2 (en) | 2016-04-29 | 2017-11-02 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| MA45341A (fr) * | 2016-06-06 | 2019-04-10 | Hutchinson Fred Cancer Res | Procédés de traitement de malignités de lymphocytes b au moyen d'une thérapie cellulaire adoptive |
| AU2017292936C1 (en) * | 2016-07-08 | 2024-05-02 | Exuma Biotech, Corp. | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
| JP7219376B2 (ja) | 2016-07-15 | 2023-02-08 | ノバルティス アーゲー | キメラ抗原受容体をキナーゼ阻害薬と併用して使用したサイトカイン放出症候群の治療及び予防 |
| BR112019002035A2 (pt) * | 2016-08-01 | 2019-05-14 | Novartis Ag | tratamento de câncer usando um receptor de antígeno quimérico em combinação com um inibidor de uma molécula pró-macrófago m2 |
| SG10201913823VA (en) | 2016-10-07 | 2020-03-30 | Novartis Ag | Chimeric antigen receptors for the treatment of cancer |
| CN106636090B (zh) * | 2016-10-11 | 2019-08-09 | 上海优卡迪生物医药科技有限公司 | 人源白细胞介素6的siRNA、重组表达CAR-T载体及其构建方法和应用 |
| US11590167B2 (en) | 2016-12-03 | 2023-02-28 | Juno Therapeutic, Inc. | Methods and compositions for use of therapeutic T cells in combination with kinase inhibitors |
| RU2019120398A (ru) * | 2016-12-03 | 2021-01-12 | Джуно Терапьютикс, Инк. | Способы определения дозировки cart-клеток |
| CN108148863B (zh) * | 2016-12-05 | 2019-12-17 | 上海优卡迪生物医药科技有限公司 | 一种封闭il6r的用于缓解crs的car-t转基因载体及其构建方法和应用 |
| CN108250301A (zh) * | 2016-12-29 | 2018-07-06 | 天津天锐生物科技有限公司 | 一种多靶点嵌合抗原受体 |
| WO2018140725A1 (en) | 2017-01-26 | 2018-08-02 | Novartis Ag | Cd28 compositions and methods for chimeric antigen receptor therapy |
| AU2018219226B2 (en) | 2017-02-07 | 2024-12-19 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents |
| WO2018157171A2 (en) * | 2017-02-27 | 2018-08-30 | Juno Therapeutics, Inc. | Compositions, articles of manufacture and methods related to dosing in cell therapy |
| ES3010559T3 (en) | 2017-02-28 | 2025-04-03 | Endocyte Inc | Compositions and methods for car t cell therapy |
| AU2018237159A1 (en) | 2017-03-22 | 2019-09-05 | Intellia Therapeutics, Inc. | Compositions and methods for immunooncology |
| AR111651A1 (es) | 2017-04-28 | 2019-08-07 | Novartis Ag | Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación |
| WO2018204413A1 (en) * | 2017-05-01 | 2018-11-08 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Targeted cytokine blockades for car-t therapy |
| CA3065120A1 (en) | 2017-06-02 | 2018-12-06 | Juno Therapeutics, Inc. | Articles of manufacture and methods for treatment using adoptive cell therapy |
| CA3064893A1 (en) * | 2017-06-08 | 2018-12-13 | Enlivex Therapeutics Ltd. | Therapeutic apoptotic cells for cancer therapy |
| JP2020530291A (ja) | 2017-08-10 | 2020-10-22 | ナショナル ユニバーシティ オブ シンガポール | Ｔ細胞受容体欠損キメラ抗原受容体ｔ細胞およびその使用方法 |
| SG11202003096UA (en) | 2017-10-02 | 2020-05-28 | Humanigen Inc | Methods of treating immunotherapy-related toxicity using a gm-csf antagonist |
| MX421741B (es) * | 2017-10-18 | 2025-03-14 | Kite Pharma Inc | Inmunoterapia con receptores de antígeno quimérico y uso de la misma |
| US11999802B2 (en) | 2017-10-18 | 2024-06-04 | Novartis Ag | Compositions and methods for selective protein degradation |
| WO2019089848A1 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Methods associated with tumor burden for assessing response to a cell therapy |
| MA50855A (fr) | 2017-11-01 | 2020-09-09 | Juno Therapeutics Inc | Procédé de génération de compositions thérapeutiques de cellules modifiées |
| US12031975B2 (en) | 2017-11-01 | 2024-07-09 | Juno Therapeutics, Inc. | Methods of assessing or monitoring a response to a cell therapy |
| AU2019209432B2 (en) | 2018-01-22 | 2026-01-08 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Methods of use for CAR T cells |
| AU2019218729B2 (en) | 2018-02-06 | 2025-12-04 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Fluorescein-specific CARs exhibiting optimal T cell function against FL-PLE labelled tumors |
| CN108300807A (zh) * | 2018-02-07 | 2018-07-20 | 安徽古生物科技有限公司 | 针对第四代嵌合抗原受体car载体pcr鉴定的方法 |
| TW202000229A (zh) | 2018-02-23 | 2020-01-01 | 美商安德賽特公司 | Car t細胞療法之順序方法 |
| WO2019170845A1 (en) * | 2018-03-09 | 2019-09-12 | Ospedale San Raffaele S.R.L. | Il-1 antagonist and toxicity induced by cell therapy |
| US11965176B2 (en) | 2018-03-14 | 2024-04-23 | Hunan Siweikang Therapeutics Co. Ltd | Modification of immune cells for reducing toxicity and uses thereof in adoptive cell therapy |
| BR112020018620A2 (pt) | 2018-03-15 | 2020-12-29 | KSQ Therapeutics, Inc. | Composições de regulação gênica e métodos para imunoterapia aprimorada |
| US10869888B2 (en) | 2018-04-17 | 2020-12-22 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expansion and uses thereof |
| EP3788369A1 (en) | 2018-05-01 | 2021-03-10 | Novartis Ag | Biomarkers for evaluating car-t cells to predict clinical outcome |
| EP3784776A4 (en) | 2018-05-23 | 2022-01-26 | National University of Singapore | Blockade of cd2 surface expression and expression of chimeric antigen receptors for immunotherapy of t-cell malignancies |
| WO2019227003A1 (en) | 2018-05-25 | 2019-11-28 | Novartis Ag | Combination therapy with chimeric antigen receptor (car) therapies |
| JP2021525530A (ja) | 2018-06-01 | 2021-09-27 | ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ | キメラ抗原受容体細胞治療薬を用いたサイトカイン放出症候群の抑制 |
| CN112512533A (zh) * | 2018-06-01 | 2021-03-16 | 妙佑医学教育研究基金会 | 用于治疗癌症的材料与方法 |
| JP7438988B2 (ja) | 2018-06-13 | 2024-02-27 | ノバルティス アーゲー | Ｂｃｍａキメラ抗原受容体及びその使用 |
| EP3826625A4 (en) | 2018-07-23 | 2022-08-24 | Magenta Therapeutics, Inc. | USE OF ANTI-CD5 ANTIBODY DRUG CONJUGATE (ADC) IN ALLOGENE CELL THERAPY |
| CN108949759B (zh) * | 2018-07-23 | 2021-06-01 | 合肥一兮生物科技有限公司 | 敲减人IL-15的siRNA、CD19 CAR表达载体、CAR-T细胞及构建方法和应用 |
| JP7539161B2 (ja) * | 2018-08-10 | 2024-08-23 | ユーティレックス カンパニー リミテッド | Ｈｌａ－ｄｒに結合するキメラ抗原受容体およびｃａｒ－ｔ細胞 |
| US12240915B2 (en) | 2018-08-30 | 2025-03-04 | Innovative Cellular Therapeutics Holdings, Ltd. | Chimeric antigen receptor cells for treating solid tumor |
| CA3111804A1 (en) * | 2018-09-10 | 2020-03-19 | Humanigen, Inc. | Methods of treating immunotherapy-related toxicity using a gm-csf antagonist |
| EP3873205A4 (en) * | 2018-10-31 | 2022-05-11 | Humanigen, Inc. | MATERIALS AND METHODS FOR TREATMENT OF CANCER |
| CA3120118A1 (en) * | 2018-11-16 | 2020-05-22 | Juno Therapeutics, Inc. | Methods of dosing engineered t cells for the treatment of b cell malignancies |
| US10918667B2 (en) | 2018-11-20 | 2021-02-16 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expressing therapeutic agent and uses thereof |
| CA3122762A1 (en) | 2018-12-12 | 2020-06-18 | Kite Pharma, Inc. | Chimeric antigen and t cell receptors and methods of use |
| JP2022524178A (ja) | 2019-01-07 | 2022-04-28 | セルリス パルティシパソエス リミターダ | タンデム受容体ｃａｒにおける二重特異性と腫瘍マイクロ環境を変調する方法 |
| CN112430579A (zh) * | 2019-08-26 | 2021-03-02 | 深圳宾德生物技术有限公司 | 靶向Her2并干扰IL-6表达的嵌合抗原受体T细胞及其制备方法和应用 |
| JP2023503161A (ja) | 2019-11-26 | 2023-01-26 | ノバルティス アーゲー | Ｃｄ１９及びｃｄ２２キメラ抗原受容体及びその使用 |
| JP7714545B2 (ja) | 2019-11-26 | 2025-07-29 | ノバルティス アーゲー | キメラ抗原受容体及びその使用 |
| US12076343B2 (en) | 2020-02-19 | 2024-09-03 | Innovative Cellular Therapeutics Holdings, Ltd. | Engineered safety in cell therapy |
| US20220169694A1 (en) * | 2020-02-20 | 2022-06-02 | Kite Pharma, Inc. | Chimeric antigen receptor t cell therapy |
| US12043654B2 (en) | 2020-06-02 | 2024-07-23 | Innovative Cellular Therapeutics Holdings, Ltd. | Anti-GCC antibody and CAR thereof for treating digestive system cancer |
| EP3988116A1 (en) * | 2020-10-23 | 2022-04-27 | Consejo Superior De Investigaciones Científicas (CSIC) | Methods and compositions for the treatment of hematologic malignancies |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| KR20230118887A (ko) | 2020-12-03 | 2023-08-14 | 센츄리 쎄라퓨틱스 인코포레이티드 | 유전자 조작 세포 및 이의 용도 |
| TW202237638A (zh) | 2020-12-09 | 2022-10-01 | 日商武田藥品工業股份有限公司 | 烏苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法 |
| WO2022133169A1 (en) | 2020-12-18 | 2022-06-23 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
| FI4284512T3 (fi) | 2021-01-28 | 2025-05-22 | Regeneron Pharma | Koostumuksia ja menetelmiä sytokiinien vapautumisoireyhtymän hoitamiseksi |
| AU2022227686A1 (en) | 2021-02-25 | 2023-07-27 | Lyell Immunopharma, Inc. | Ror1 targeting chimeric antigen receptor |
| WO2023004055A1 (en) * | 2021-07-21 | 2023-01-26 | The Cleveland Clinic Foundation | Metabolic and inflammatory markers for car-t cell therapy |
| JP2024541980A (ja) * | 2021-10-27 | 2024-11-13 | ラッシュ ユニヴァーシティ メディカル センター | サイトカインストームの影響を治療する方法 |
| US20230296610A1 (en) * | 2022-02-15 | 2023-09-21 | Kite Pharma, Inc. | Predicting adverse events from immunotherapy |
| JP2025535448A (ja) * | 2022-10-20 | 2025-10-24 | マイクロ クリスパー プライベート リミテッド | 免疫療法におけるサイトカイン放出症候群の軽減 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| DE1248112T1 (de) | 1987-04-27 | 2003-03-20 | Inverness Medical Switzerland | Immunochromatographische Spezifischebindungsassayvorrichtung |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5199942A (en) | 1991-06-07 | 1993-04-06 | Immunex Corporation | Method for improving autologous transplantation |
| GB9125768D0 (en) | 1991-12-04 | 1992-02-05 | Hale Geoffrey | Therapeutic method |
| EP0746609A4 (en) | 1991-12-17 | 1997-12-17 | Genpharm Int | NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES |
| US6267722B1 (en) | 1998-02-03 | 2001-07-31 | Adeza Biomedical Corporation | Point of care diagnostic systems |
| US6656745B1 (en) | 2000-06-02 | 2003-12-02 | Francis X. Cole | Devices and methods for a multi-level, semi-quantitative immunodiffusion assay |
| AU2008207646A1 (en) * | 2001-10-04 | 2008-09-25 | Genetics Institute, Llc | Methods and compositions for modulating interleukin-21 receptor activity |
| GB2401040A (en) | 2003-04-28 | 2004-11-03 | Chugai Pharmaceutical Co Ltd | Method for treating interleukin-6 related diseases |
| US7749999B2 (en) * | 2003-09-11 | 2010-07-06 | Itherx Pharmaceuticals, Inc. | Alpha-ketoamides and derivatives thereof |
| EP2280285A1 (en) * | 2003-09-15 | 2011-02-02 | Oklahoma Medical Research Foundation | Method of using cytokine assays to diagnose, treat, and evaluate inflammatory and autoimmune diseases |
| US7189522B2 (en) | 2005-03-11 | 2007-03-13 | Chembio Diagnostic Systems, Inc. | Dual path immunoassay device |
| EP2164514B1 (en) | 2007-05-21 | 2016-12-14 | AlderBio Holdings LLC | Antibodies to il-6 and use thereof |
| WO2008157282A1 (en) * | 2007-06-18 | 2008-12-24 | Genentech, Inc. | Biological markers predictive of rheumatoid arthritis response to b-cell antagonists |
| US9452227B2 (en) * | 2008-11-25 | 2016-09-27 | Alderbio Holdings Llc | Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments |
| MX2011005396A (es) | 2008-11-25 | 2011-06-09 | Alder Biopharmaceuticals Inc | Antagonistas de il-6 para aumentar la albumina y/o disminuir la crp. |
| WO2010075249A2 (en) * | 2008-12-22 | 2010-07-01 | Genentech, Inc. | A method for treating rheumatoid arthritis with b-cell antagonists |
| EP2504031A4 (en) | 2009-11-24 | 2013-06-26 | Alderbio Holdings Llc | ANTI-IL-6 ANTIBODIES AND THEIR USE |
| PH12013501201A1 (en) * | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| WO2013033626A2 (en) | 2011-08-31 | 2013-03-07 | Trustees Of Dartmouth College | Nkp30 receptor targeted therapeutics |
| EA026436B9 (ru) | 2012-07-04 | 2017-07-31 | Ин Энд Тек С.Р.Л. | Шарнирная петля для вращательного движения двери, в частности армированной двери |
| ES2941370T3 (es) | 2012-07-13 | 2023-05-22 | Univ Pennsylvania | Control de la toxicidad para la actividad antitumoral de los CAR |
-
2013
- 2013-07-12 ES ES21215762T patent/ES2941370T3/es active Active
- 2013-07-12 JP JP2015521838A patent/JP6382191B2/ja active Active
- 2013-07-12 EP EP24202493.3A patent/EP4461308B1/en active Active
- 2013-07-12 ES ES13817210T patent/ES2859522T3/es active Active
- 2013-07-12 SI SI201332036T patent/SI4019041T1/sl unknown
- 2013-07-12 PL PL24202493.3T patent/PL4461308T3/pl unknown
- 2013-07-12 EP EP20158930.6A patent/EP3721901A1/en active Pending
- 2013-07-12 DK DK18154090.7T patent/DK3338794T3/da active
- 2013-07-12 AU AU2013289967A patent/AU2013289967B2/en active Active
- 2013-07-12 FI FIEP24202493.3T patent/FI4461308T3/fi active
- 2013-07-12 SI SI201332104T patent/SI4461308T1/sl unknown
- 2013-07-12 CN CN202010124264.3A patent/CN111467494B/zh active Active
- 2013-07-12 US US14/410,659 patent/US20150202286A1/en not_active Abandoned
- 2013-07-12 CN CN201810348463.5A patent/CN108379586A/zh active Pending
- 2013-07-12 DK DK21215762.2T patent/DK4019041T3/da active
- 2013-07-12 PT PT212157622T patent/PT4019041T/pt unknown
- 2013-07-12 LT LTEP24202493.3T patent/LT4461308T/lt unknown
- 2013-07-12 KR KR1020157003078A patent/KR102204029B1/ko active Active
- 2013-07-12 EP EP21215762.2A patent/EP4019041B1/en active Active
- 2013-07-12 EA EA201590210A patent/EA201590210A1/ru unknown
- 2013-07-12 HR HRP20250822TT patent/HRP20250822T1/hr unknown
- 2013-07-12 MX MX2015000438A patent/MX2015000438A/es active IP Right Grant
- 2013-07-12 FI FIEP21215762.2T patent/FI4019041T3/fi active
- 2013-07-12 IN IN11155DEN2014 patent/IN2014DN11155A/en unknown
- 2013-07-12 CA CA2878928A patent/CA2878928C/en active Active
- 2013-07-12 ES ES24202493T patent/ES3032321T3/es active Active
- 2013-07-12 PT PT138172101T patent/PT2872171T/pt unknown
- 2013-07-12 HR HRP20230297TT patent/HRP20230297T1/hr unknown
- 2013-07-12 ES ES18154090T patent/ES2778701T3/es active Active
- 2013-07-12 EP EP13817210.1A patent/EP2872171B1/en active Active
- 2013-07-12 LT LTEP18154090.7T patent/LT3338794T/lt unknown
- 2013-07-12 LT LTEP13817210.1T patent/LT2872171T/lt unknown
- 2013-07-12 DK DK13817210.1T patent/DK2872171T3/da active
- 2013-07-12 PT PT242024933T patent/PT4461308T/pt unknown
- 2013-07-12 BR BR112015000660A patent/BR112015000660A8/pt not_active Application Discontinuation
- 2013-07-12 EP EP18154090.7A patent/EP3338794B1/en not_active Revoked
- 2013-07-12 DK DK24202493.3T patent/DK4461308T3/da active
- 2013-07-12 WO PCT/US2013/050267 patent/WO2014011984A1/en not_active Ceased
- 2013-07-12 HU HUE24202493A patent/HUE072215T2/hu unknown
- 2013-07-12 CN CN201380037301.5A patent/CN104427997B/zh active Active
- 2013-07-12 PL PL21215762.2T patent/PL4019041T3/pl unknown
- 2013-07-12 HU HUE18154090A patent/HUE048947T2/hu unknown
- 2013-07-12 LT LTEP21215762.2T patent/LT4019041T/lt unknown
- 2013-07-12 HU HUE21215762A patent/HUE061555T2/hu unknown
- 2013-07-12 HU HUE13817210A patent/HUE053556T2/hu unknown
- 2013-07-12 CN CN202010124303.XA patent/CN111481667A/zh active Pending
- 2013-07-12 PL PL13817210T patent/PL2872171T3/pl unknown
- 2013-07-12 PT PT181540907T patent/PT3338794T/pt unknown
-
2015
- 2015-01-09 MX MX2019014761A patent/MX2019014761A/es unknown
-
2018
- 2018-04-26 JP JP2018085102A patent/JP6563554B2/ja active Active
- 2018-04-26 US US15/963,728 patent/US11273219B2/en active Active
- 2018-05-07 US US15/972,972 patent/US10603378B2/en active Active
- 2018-06-04 AU AU2018203924A patent/AU2018203924B2/en active Active
- 2018-08-09 JP JP2018150287A patent/JP2019006782A/ja not_active Withdrawn
-
2019
- 2019-07-24 JP JP2019136179A patent/JP7034125B2/ja active Active
-
2022
- 2022-02-22 US US17/677,208 patent/US20230013642A1/en not_active Abandoned
- 2022-03-01 JP JP2022030740A patent/JP7682820B2/ja active Active
-
2024
- 2024-11-06 JP JP2024194132A patent/JP2025013518A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230013642A1 (en) | Toxicity Management for Anti-Tumor Activity of CARs | |
| JP2022537700A (ja) | 細胞媒介細胞傷害性療法と生存促進性ｂｃｌ２ファミリータンパク質の阻害剤との併用療法 | |
| HK40116181B (en) | Toxicity management for anti-tumor activity of cars | |
| HK40116181A (en) | Toxicity management for anti-tumor activity of cars | |
| HK40069741A (en) | Toxicity management for anti-tumor activity of cars | |
| HK40069741B (en) | Toxicity management for anti-tumor activity of cars | |
| HK40039113A (en) | Toxicity management for anti-tumor activity of cars | |
| HK1253365B (en) | Toxicity management for anti-tumor activity of cars | |
| EA041322B1 (ru) | Контроль над токсичностью в случае противоопухолевой активности химерных антигенных рецепторов (car) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20180618 |
|
| EEER | Examination request |
Effective date: 20180618 |
|
| EEER | Examination request |
Effective date: 20180618 |
|
| EEER | Examination request |
Effective date: 20180618 |
|
| EEER | Examination request |
Effective date: 20180618 |